

Company name---Purple Biotech * Website-<https://purple-biotech.com/>-- *

CEO name---Gil Efron

Select a CATEGORY: Biotech/Pharma

Select one SESSION per abstract from the list below *

“Redefining the Fight Against Cancer: New Targets, New Modalities.”

- **Executive Summary / Investment Rational:** Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.
Purple Biotech is developing CAPTN-3, a next-generation tri-specific antibody platform that enables tumor-directed, restricted activation of both adaptive and innate immunity by combining a tumor-targeting antibody with a conditionally activated T cell engager and an NK-cell engager, thereby enhancing efficacy while improving the therapeutic index.
Multi-specific antibodies represent a new frontier in immunotherapy, with the potential to overcome key barriers in oncology treatment by amplifying anti-cancer activity across multiple immune pathways while maintaining safety. While bispecifics are gaining traction through recent drug approvals and licensing and M&A activity, tri-specific antibodies are emerging as the next wave of innovation.
- **Core Technology:** What is the technology, its uniqueness, and its value proposition?
A modular tri-specific antibody scaffold of antibodies integrating a masked, protease-activated CD3 arm, a tumor-associated antigen targeting arm, and an NK-cell engaging arm (e.g., NKG2A), including a built-in human serum albumin module designed to extend half-life. This design enables potent immune activation exclusively within the tumor microenvironment while minimizing systemic toxicity.
- **Product Profile/Pipeline:** Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.
Purple Biotech is advancing a pipeline of tri-specific immunotherapies for solid tumors. The first candidate, IM1240 (capped-CD3×5T4×NKG2A), is in IND-enabling development toward a Phase 1 clinical trial, while its second candidate, IM1305 (capped-CD3×TROP2×NKG2A), has demonstrated strong in-vivo efficacy. The antibody targets (5T4 & TROP2) are highly expressed in a large number of cancer tissues, potentially addressing large unmet oncology markets. Near-term milestones include IND submission and first-in-human data, supporting partnering, co-development, and licensing opportunities across high-value solid tumor indications.
- **Business Strategy:** Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.
Purple Biotech is advancing CAPTN-3 assets to early clinical proof-of-concept while leveraging the modular platform for strategic partnerships. Short-term value is generated through IND and Phase 1 data and collaboration agreements; long-term revenue derives from licensing, co-development, and a growing pipeline of platform-derived immunotherapies.
- **What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans**
Near-term plans include IND submission and Phase 1 initiation for IM1240, advancement of IM1305, and AI-enabled expansion of the CAPTN-3 platform. Organizational focus centers on expanding product offerings to increase partnership opportunities, and follow-on financing leveraging early pre-clinical and clinical proof-of-concept.